SELB earnings

– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen

– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its cli

- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 - - Selecta to host conference call today at 8:30 AM ET - WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter

WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today  announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (inter

--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II--In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II--75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of therapy with no infusion reactions or new safety signals--Favorable safety profile with 3.4% of patients with infusion reactions at high dose--Selecta will host a conference call and webcast today at 8:30 AM ET / 2:30 PM CET WATERTOWN, Mass. and STOCKHOLM, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB) and Sobi®, today

- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - - Continue to enroll patients in ReiMMAgine, the Phase 1/2 clinical trial of SEL-302 for the treatment of methylmalonic acidemia (MMA) - - IND enabling studies expected to commence in 2023 for interleukin-2 (IL-2) candidate to be studied in combination with ImmTOR™, as well as IgA protease candidate for the treatment of IgA Nephropathy - - As of December 31, 2022, Selecta had approximately $136.2 million in cash, cash equivalents, restricted cash and marketable securities, which is expected to provide runway into mid-2024 - - Selecta to host conference call toda

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2022 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-

– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 – – SEL-302, Selecta's wholly owned gene therapy in combination with ImmTOR for the treatment of Methylmalonic Acidemia (MMA), remains on track to begin a Phase 1 trial in Q4 2022 – – As of September 30, 2022, Selecta had approximately $148.0 million in cash, cash equivalents, restricted cash and marketable securities, which is expected to provide runway into mid-2024 – – Candidate selection for an IL-2 and IgA protease expected by year-end 2022 –   – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --

WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that it plans to host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may ac

– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline data readout in Q1 2023 – – Sarepta extends Option and License agreement in exchange for a $2 million payment and notified Selecta of the achievement of certain pre-clinical milestones triggering a $4 million milestone payment obligation – – SEL-302, Selecta's wholly owned gene therapy in combination with ImmTOR for the treatment of Methylmalonic Acidemia (MMA) remains on track to initiate a Phase 1 trial in Q4 2022 – – As of June 30, 2022, Selecta had approximately $143.4 million in cash, ca

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that it plans to host a conference call on Thursday, August 4, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by d

– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – – Completed underwritten offering, raising approximately $38.7 million in gross proceeds, extending runway into mid-2024 – – As of April 11, 2022, Selecta had approximately $154.2 million in cash, cash equivalents, restricted cash and marketable securities – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic

WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, May 5, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088

– U.S. Food and Drug Administration ("FDA") removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia ("MMA")- -Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-specific Tregs and improve durability of immune tolerance (ImmTOR-IL)- -Further validated and expanded the ImmTOR precision immune tolerance platform through numerous strategic collaborations - -Completed enrollment in DISSOLVE I, the first of two studies in the Phase 3 program evaluating SEL-212 for chronic refractory gout- -Presented topline data for SEL-399 human proof-of-concept data in healthy volunteers where ImmTOR was obse

WATERTOWN, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated, precision immune tolerance platform, ImmTOR®, to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, March 10, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialin

-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform- -Reported topline data from SEL-399 (empty AAV8 capsid in combination with ImmTOR); Selecta intends continued expansion of ImmTOR platform across gene therapy pipeline- -Continued execution of multiple preclinical programs toward IND- -Further strengthened leadership team with the appointment of Kevin Tan as CFO- -As of September 30, 2021, Selecta had approximately $140.0 million in cash, cash equivalents, restricted cash and marketable securities which is expected to provide runway into the second quarter of 2023- WATERTOWN, Mass., Nov. 09, 2021

- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 - - With co-administration of AAV8 empty capsids and ImmTOR, Selecta observed dose-dependent response to ImmTOR with a safety profile in line with prior human studies - - Based on these data Selecta intends to rapidly advance its wholly owned gene therapy pipeline, and continue to selectively evaluate gene therapy partnership opportunities utilizing ImmTOR - - Selecta to host conference call and webcast today at 8:30 a.m. ET - WATERTOWN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology comp

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-00

IND filing for wholly owned gene therapy program, SEL-302 (MMA-101, in combination with ImmTOR) in methylmalonic acidemia (MMA) expected during the third quarter of 2021; Manufacturing issue has been resolved, with a new completed lot undergoing final release testingSEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021Selecta achieved $3 million milestone payment from Sarepta Therapeutics related to successfully meeting the criteria for a preclinical studyAs of June 30, 2021, Selecta had approximately $151.5 million in cash, cash equivalents, and marketable securities which is expected to provide runway into the third quarter of 2023

WATERTOWN, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, August 12, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (i